Sensoreal
Sensoreal is a company dedicated to developing innovative point-of-care diagnostic solutions, including rapid, affordable, and versatile microfluidic devices for detecting toxins, infectious diseases, and antimicrobial resistance. Their mission is to provide lab-grade precision in various environments, supporting global health initiatives and space research.
Industries
Nr. of Employees
small (1-50)
Products
Semi-quantitative field-deployable shellfish toxin test kit with reader
A semi-quantitative, rapid test kit for detection of paralytic shellfish poisoning (PSP) toxins in shellfish, paired with a reader that provides semi-quantitative results and wireless data transmission.
Microfluidic blood assay cartridges (space-validated prototypes)
Microfluidic cartridges developed and tested for blood assays with demonstrated functionality in zero-gravity testing on the International Space Station.
Portable nucleic acid detection system (development)
In-development portable nucleic acid detection system intended for point-of-care applications, supported by space technology development funding.
Instrument-free direct bacteria capture platform (commercialization effort)
A platform concept for capturing bacteria directly from samples without laboratory instrumentation, intended to support rapid point-of-care bacterial diagnostics.
Semi-quantitative field-deployable shellfish toxin test kit with reader
A semi-quantitative, rapid test kit for detection of paralytic shellfish poisoning (PSP) toxins in shellfish, paired with a reader that provides semi-quantitative results and wireless data transmission.
Microfluidic blood assay cartridges (space-validated prototypes)
Microfluidic cartridges developed and tested for blood assays with demonstrated functionality in zero-gravity testing on the International Space Station.
Portable nucleic acid detection system (development)
In-development portable nucleic acid detection system intended for point-of-care applications, supported by space technology development funding.
Instrument-free direct bacteria capture platform (commercialization effort)
A platform concept for capturing bacteria directly from samples without laboratory instrumentation, intended to support rapid point-of-care bacterial diagnostics.
Services
Development of wet-lab assays adapted to capillary-driven microfluidic chips including reagent validation, protocol development, and statistical analysis.
In-house prototyping, iterative device design, and small-batch manufacturing to support product development and pre-commercial trials.
Organization and execution of side-by-side testing with reference laboratory methods and coordination with federal or accredited labs for comparative studies.
Partnership execution for validation studies and participation in government innovation challenges and funded programs to advance pre-commercial testing and trials.
Development of wet-lab assays adapted to capillary-driven microfluidic chips including reagent validation, protocol development, and statistical analysis.
In-house prototyping, iterative device design, and small-batch manufacturing to support product development and pre-commercial trials.
Organization and execution of side-by-side testing with reference laboratory methods and coordination with federal or accredited labs for comparative studies.
Partnership execution for validation studies and participation in government innovation challenges and funded programs to advance pre-commercial testing and trials.
Expertise Areas
- Point-of-care diagnostic development
- Microfluidic cartridge design
- Assay development and clinical validation
- Multiplex biomarker assays
Key Technologies
- Capillary-driven microfluidics
- Self-powered microfluidic cartridges
- Multiplex immunoassay methods
- Portable nucleic acid detection
News & Updates
Formed global research collaborations to validate and test PSP Alert kit for detecting PSP toxins in shellfish.
Presented their PSP Alert kit to industry stakeholders, generating interest and networking opportunities.
Their proposal for the PSP Alert pre-commercialization trial was pre-qualified with a high score, seeking government testing partners.
Developing a new environmental toxin test with funding from the Canadian Food Inspection Agency.
Awarded the MI4 Innovation Prize for demonstrating their microfluidics platform.
Recognized as a top 10 finalist in a global impact acceleration program.
Formed global research collaborations to validate and test PSP Alert kit for detecting PSP toxins in shellfish.
Presented their PSP Alert kit to industry stakeholders, generating interest and networking opportunities.
Their proposal for the PSP Alert pre-commercialization trial was pre-qualified with a high score, seeking government testing partners.
Developing a new environmental toxin test with funding from the Canadian Food Inspection Agency.
Awarded the MI4 Innovation Prize for demonstrating their microfluidics platform.
Recognized as a top 10 finalist in a global impact acceleration program.